StatLab Medical Products, a prominent developer and manufacturer of diagnostic supplies and equipment, has announced the appointment of Sung-Dae (Dae) Hong as its new Chief Executive Officer (CEO) and Board Member. This appointment, effective from August 28, 2023, comes as Joe Bernardo, who was serving as the Interim CEO, continues his role as Board Chairman.
Key Highlights
- Sung-Dae Hong has been appointed as the new CEO of StatLab Medical Products, effective August 28, 2023.
- Joe Bernardo, who was serving as the Interim CEO, will continue in his role as Board Chairman.
- Dae brings over two decades of global strategy and general management experience to StatLab.
- Previously, Dae served as the President of Laboratory Products at Thermo Fisher Scientific.
- Dae’s appointment is expected to drive strategic growth and transformation in the organization.
Source: Business Wire
Notable Quotes
- “The Board and I are confident that Dae is not only an excellent fit to lead our global business, but also that his dynamic leadership will ignite transformation in the organization around him.” – Joe Bernardo, Board Chairman
- “I am incredibly honored to join StatLab and to partner with this talented team with a shared goal of delivering value to our customers, stakeholders, and ultimately, each other, as we strive to build a global organization that recognizes and celebrates growth, impact, and progress in everything we do.” – Sung-Dae Hong, CEO
SoH's Take
- The appointment of Sung-Dae Hong, with his extensive experience in global strategy and management, signals StatLab’s intent to drive strategic growth and transformation. His previous role at Thermo Fisher Scientific, overseeing a diversified global business, makes him well-suited to lead StatLab’s expansion efforts.
- The company’s decision to bring in a leader with a strong background in M&A and growth strategy suggests that StatLab may be eyeing further acquisitions or strategic partnerships in the near future.
